Loading clinical trials...
Loading clinical trials...
A Single-arm, Multi-centre Trial to Evaluate Efficacy and Safety of Imlifidase in Highly Sensitised Children (1-17 Years) Receiving a Kidney Transplant With Positive Crossmatch Against a Living or Deceased Donor Converted to Negative After Imlifidase Treatment
Conditions
Interventions
Imlifidase
Locations
5
Finland
HUS, Helsinki University Hospital
Helsinki, Finland
Robert Debre University Hospital
Paris, France
Hospital Unviersitari Vall d'Hebron, Nefrología Pediátrica
Barcelona, Spain
Karolinska University Hospital
Huddinge, Stockholm County, Sweden
Great Ormond Street Hospital for Children NHS Foundation Trust
London, United Kingdom
Start Date
June 2, 2023
Primary Completion Date
February 28, 2027
Completion Date
August 31, 2031
Last Updated
April 24, 2026
Lead Sponsor
Hansa Biopharma AB
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions